[A21-93] Empagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V
Last updated 06.01.2022
Project no.:
A21-93
Commission:
Commission awarded on 13.07.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Heart and circulation
Indication:
Adults with symptomatic chronic heart failure with reduced ejection fraction
Result of dossier assessment:
Hint of non-quantifiable added benefit
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A16-12 | Empagliflozin - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A14-26 | Empagliflozin - Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |
| A21-148 | Empagliflozin (heart failure) - Addendum to Commission A21-93 | Commission completed |
| A23-142 | Empagliflozin (type 2 diabetes mellitus in children and adolescents) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-78 | Empagliflozin (renal insufficiency) - Benefit assessment according to § 35a Social Code Book V | Commission completed |
| A22-39 | Empagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2022-01-06 A G-BA decision was published.